Literature DB >> 30941053

Computation of Robust Minimal Intervention Sets in Multi-Valued Biological Regulatory Networks.

Hooman Sedghamiz1, Matthew Morris1, Darrell Whitley2, Travis J A Craddock3,4,5,6, Michael Pichichero7, Gordon Broderick1,8.   

Abstract

Enabled by rapid advances in computational sciences, in silico logical modeling of complex and large biological networks is more and more feasible making it an increasingly popular approach among biologists. Automated high-throughput, drug target identification is one of the primary goals of this in silico network biology. Targets identified in this way are then used to mine a library of drug chemical compounds in order to identify appropriate therapies. While identification of drug targets is exhaustively feasible on small networks, it remains computationally difficult on moderate and larger models. Moreover, there are several important constraints such as off-target effects, efficacy and safety that should be integrated into the identification of targets if the intention is translation to the clinical space. Here we introduce numerical constraints whereby efficacy is represented by efficiency in response and robustness of outcome. This paper introduces an algorithm that relies on a Constraint Satisfaction (CS) technique to efficiently compute the Minimal Intervention Sets (MIS) within a set of often complex clinical safety constraints with the aim of identifying the smallest least invasive set of targets pharmacologically accessible for therapy that most efficiently and reliably achieve the desired outcome.

Entities:  

Keywords:  algorithms; drug therapy; experimental design; logical modeling; signaling networks; target identification

Year:  2019        PMID: 30941053      PMCID: PMC6433979          DOI: 10.3389/fphys.2019.00241

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  2 in total

1.  Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer.

Authors:  Eileen H Shinn; Brooke E Busch; Neda Jasemi; Cole A Lyman; J Tory Toole; Spencer C Richman; William Fraser Symmans; Mariana Chavez-MacGregor; Susan K Peterson; Gordon Broderick
Journal:  Front Psychol       Date:  2022-07-12

2.  Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.

Authors:  Spencer Richman; Cole Lyman; Matthew Morris; Gordon Broderick; Anastasia Nesterova; Anton Yuryev; Hongbao Cao; Chris Cheadle; Gary Skuse
Journal:  NPJ Syst Biol Appl       Date:  2022-10-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.